Clinical Trial Update: Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial update for autologous dendritic cell-tumor cell immunotherapy in metastatic melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous dendritic cell-tumor cell immunotherapy

Snippet

Sponsor: Lisata Therapeutics, Inc. | Conditions: Stage IV Melanoma, Stage III Melanoma | Phase 3 | Status: TERMINATED